Neisseria gonorrhoeae

Neisseria gonorrhoeae is the bacterium behind gonorrhea, one of the oldest and most common sexually transmitted infections in the world. Nicknamed "the gonococcus" (and the infection it causes long known as "the clap"), it is a remarkably clever germ: it hides from the immune system so well that people can be infected again and again with no lasting protection, and it has systematically defeated nearly every antibiotic thrown at it over the past century. Today it stands out as one of the most urgent drug-resistance threats in medicine — a once-easily-cured infection that public-health experts now worry could become untreatable. This page explains, in plain language, what this bacterium is, the infection it causes, the serious problems it creates when it goes untreated, and why doctors and global health agencies are so concerned about resistance.

Table of Contents

  1. What Neisseria gonorrhoeae Is
  2. Why There Is No Lasting Immunity (or Vaccine)
  3. Gonorrhea: The Infection It Causes
  4. When It Spreads: PID, Infertility & Beyond
  5. The Chlamydia Co-Infection
  6. How It Is Diagnosed
  7. The Antibiotic-Resistance Crisis
  8. Treatment Today
  9. Screening & Prevention
  10. Research Papers
  11. Connections
  12. Featured Videos

What Neisseria gonorrhoeae Is

Neisseria gonorrhoeae is a Gram-negative bacterium — meaning it has a particular kind of thin-walled, double-membraned outer coat that stains pink rather than purple under a microscope. Its shape is distinctive: the cells are round-to-oval and pair up side by side, looking like two coffee beans or two kidneys pressed together. Microbiologists call this a diplococcus ("diplo-" for double, "-coccus" for round). That coffee-bean-pair appearance, sitting inside the body's white blood cells, is a classic clue on a laboratory slide.

It is an obligate human pathogen. That phrase means it has no other home: it does not live in soil, water, food, or animals, and it cannot survive for long outside the warm, moist surfaces of the human body. Humans are its only reservoir, which is actually good news for control — there is no environmental source constantly reseeding infections. It spreads almost entirely through direct intimate contact.

The bacterium is armed with tiny hair-like grappling hooks called pili (type IV pili) and surface proteins known as Opa proteins. These let it latch tightly onto the cells lining the genital tract, throat, rectum, and eye, and then burrow in. It is also equipped to scavenge iron directly from human proteins and to fend off the immune system's first responders. In short, it is exquisitely specialized to live on and infect people, and nothing else.

Why There Is No Lasting Immunity (or Vaccine)

With most infections, catching the germ once teaches your immune system to recognize and destroy it faster the next time — that is the whole principle behind immunity and vaccines. Gonorrhea breaks this rule. People can be reinfected over and over throughout their lives, and a past infection provides essentially no meaningful protection against the next one.

The reason is a trick called antigenic variation. The parts of the bacterium that the immune system learns to target — especially those pili and Opa surface proteins — are not fixed. The gonococcus constantly shuffles and rewrites the genes that build them, so that the next generation of bacteria wears a slightly different "coat." By the time your immune system has produced antibodies against one version, the bacteria attacking you look different. It is a moving target that changes disguises faster than the body can pin it down. The germ can also switch surface features on and off entirely (phase variation), adding to the camouflage.

This is exactly why there is still no licensed vaccine against gonorrhea, despite more than a century of effort — the usual strategy of training immunity against a stable surface marker simply does not work when the marker keeps changing. There is, however, a genuinely hopeful lead. Because N. gonorrhoeae is a close cousin of the meningitis bacterium Neisseria meningitidis, researchers noticed that people vaccinated with certain meningococcal B (MenB) vaccines — which are built from the bacterial outer membrane — seemed to have modestly fewer gonorrhea cases. A large New Zealand study estimated roughly 30% protection from one such vaccine (see Research Papers). That is far from perfect, but it was the first real signal that a gonorrhea vaccine might be possible, and it has energized the field. As of now, though, prevention still depends on behavior and testing, not a shot.

Gonorrhea: The Infection It Causes

Gonorrhea is the disease caused by this bacterium, and it is extremely common. It is the second most frequently reported bacterial STI in the United States (after chlamydia), with more than 700,000 cases reported in recent years — and because so many infections cause no symptoms and never get tested, the true number is considerably higher. Globally, the World Health Organization has estimated on the order of 82 million new infections a year among adults. It spreads through vaginal, anal, and oral sex, and a pregnant woman can pass it to her baby during birth.

What the infection feels like depends heavily on who has it and where the bacteria land:

The take-home message is that "no symptoms" does not mean "no infection." A large share of gonorrhea — especially in women and at the throat and rectum — is quietly carried and unknowingly passed on, which is precisely why screening (testing people who feel fine) is such an important tool.

When It Spreads: PID, Infertility & Beyond

Left untreated, gonorrhea does not just stay put. The same features that make it a good colonizer let it climb deeper into the body, and the consequences can be permanent.

Pelvic inflammatory disease and infertility (women)

In women, untreated cervical infection can ascend from the cervix up into the uterus, fallopian tubes, and ovaries, causing pelvic inflammatory disease (PID). PID is a serious inflammation that can scar the delicate fallopian tubes. That scarring is a leading cause of infertility and of ectopic pregnancy (a dangerous pregnancy that implants in the tube instead of the uterus), and it can leave a woman with chronic pelvic pain. Because the original infection is so often silent, a woman may not learn anything is wrong until she has trouble getting pregnant — making this one of the most consequential "invisible" complications in all of infectious disease.

Epididymitis (men)

In men, the infection can spread to the epididymis, the coiled tube behind the testicle where sperm mature, causing painful swelling known as epididymitis. It is usually one-sided, with testicular pain and tenderness. Though far less common than PID, untreated epididymitis can, in rare cases, contribute to fertility problems.

Disseminated gonococcal infection (the arthritis–dermatitis syndrome)

In a small fraction of cases, the bacteria break out of the genital tract and spread through the bloodstream — a condition called disseminated gonococcal infection (DGI). The classic presentation is often called the arthritis–dermatitis syndrome, and it is a triad worth recognizing: (1) fever and joint pain, often with inflammation of the tendon sheaths (tenosynovitis) around the wrists, ankles, and fingers; (2) a scattering of skin lesions — small pustules or bumps, sometimes with a dark or hemorrhagic center; and (3) migrating joint aches that can settle into a genuinely infected, swollen joint (septic arthritis). DGI is more common in women and, in rare cases, can reach the heart valves (endocarditis) or the lining of the brain (meningitis). People with certain inherited deficiencies of the immune system's complement proteins are especially prone to it. DGI is a medical situation that requires prompt intravenous antibiotics.

Newborn eye infection (ophthalmia neonatorum)

A baby born to a mother with untreated gonorrhea can pick up the bacteria in the birth canal, leading to a severe eye infection called gonococcal ophthalmia neonatorum — a red, swollen, pus-producing conjunctivitis that appears in the first days of life and, if not treated urgently, can scar the cornea and cause blindness. This threat was so feared historically that it drove one of the earliest public-health preventive measures: placing antibiotic (or, long ago, silver nitrate) drops in every newborn's eyes at birth. In the United States, prophylactic eye ointment for newborns remains standard practice, which is why this once-common cause of childhood blindness is now rare here.

The Chlamydia Co-Infection

Gonorrhea rarely travels alone. It very often shows up together with chlamydia (caused by the bacterium Chlamydia trachomatis), another extremely common STI that spreads the same way and causes overlapping problems — including its own major contribution to PID and infertility. The two infections are found together often enough that, for many years, standard practice was to treat for both at the same time whenever gonorrhea was diagnosed, without waiting to confirm chlamydia.

This dual-coverage habit shaped gonorrhea treatment for a long time (the old regimen paired an injection for gonorrhea with an oral drug that also covered chlamydia). As explained in the treatment section below, the details have since changed — but the underlying point still holds: because co-infection is so common, testing for and treating chlamydia is a routine part of managing gonorrhea, and anyone diagnosed with one should be checked for the other (and for other STIs, including syphilis and HIV).

How It Is Diagnosed

Diagnosis today is far easier and more accurate than it used to be. The workhorse test is the NAAT, short for nucleic acid amplification test. Instead of trying to grow the fragile bacteria in a lab, a NAAT detects the germ's genetic material (its DNA or RNA) and amplifies it millions of times, so even a small number of organisms can be found reliably. NAATs are highly sensitive and specific and are the recommended first-line test.

Their other big advantage is convenience and reach:

There is one important reason the old-fashioned method — bacterial culture, actually growing the organism on a plate — has not gone away. A NAAT tells you the bacteria are present, but it cannot (in routine use) tell you which antibiotics will still work. Only a culture lets the lab test the live bacteria against different drugs (antimicrobial susceptibility testing). In the era of drug resistance, culture has become vital again — both to guide treatment when a first-line drug fails and to feed the national and global surveillance networks that track resistance. In men with obvious symptoms, a quick Gram stain of urethral discharge showing those tell-tale coffee-bean pairs inside white blood cells can also give a fast presumptive diagnosis.

The Antibiotic-Resistance Crisis

This is the defining story of Neisseria gonorrhoeae in modern medicine, and it is genuinely alarming. Gonorrhea has developed resistance to essentially every class of antibiotic ever used to treat it, one after another, in a decades-long chase that public-health officials keep losing ground in. The gonococcus is unusually good at acquiring resistance — it readily picks up resistance genes from other bacteria (including its harmless Neisseria relatives in the throat) and rapidly mutates its own drug targets.

The history reads like a graveyard of once-reliable drugs:

The fear driving current guidelines is untreatable gonorrhea. Strains that resist even ceftriaxone — sometimes called extensively drug-resistant (XDR) gonorrhea — have already been detected in several countries. Because ceftriaxone is the last dependable drug, losing it would leave clinicians with very few options for a common infection.

This is why the global health community treats gonorrhea as a top-tier threat. The World Health Organization lists N. gonorrhoeae as a "priority pathogen" for which new antibiotics are urgently needed, and it runs a worldwide surveillance program (the Gonococcal Antimicrobial Surveillance Programme, or GASP) to track resistance in real time and sound the alarm early. In the United States, the CDC classifies drug-resistant gonorrhea as an "urgent threat" — its highest category of concern. The message from both is the same: this is a race against a fast-evolving germ, and preserving the drugs that still work has become a public-health priority in its own right.

Treatment Today

Because of everything above, gonorrhea treatment is now built around protecting the one drug that still reliably works. In 2020 the CDC updated its guidance to a simpler, more focused approach (see Research Papers):

A few practical points round out modern care. A test of cure (rechecking to confirm the infection cleared) is recommended especially for throat infections, which are harder to cure. Because reinfection is so common, retesting about three months later is advised. And treating the infection is only half the job: sexual partners must be tested and treated too, or the infection simply bounces back and forth. In many places, doctors can provide expedited partner therapy — giving the patient medication or a prescription to pass to their partner — to help break that cycle. Anyone treated should also avoid sex until they and their partners have completed treatment.

Screening & Prevention

Because so much gonorrhea is silent, screening people who feel perfectly well is one of the most effective tools against it. General guidance from public-health authorities includes:

Prevention itself rests on familiar but genuinely effective measures:

None of this is exotic. The reason these basics matter so much is precisely because the alternative — relying on a cure — is exactly what the resistance crisis is putting at risk. In a world where the last effective antibiotic is under threat, preventing infection in the first place has never been more important.

Research Papers

  1. Workowski KA, Bachmann LH, Chan PA, Johnston CM, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports. 2021;70(4):1–187. doi:10.15585/mmwr.rr7004a1 — The comprehensive current CDC guidelines for diagnosing and managing gonorrhea and other STIs.
  2. St. Cyr S, Barbee L, Workowski KA, Bachmann LH, et al. Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morbidity and Mortality Weekly Report. 2020;69(50):1911–1916. doi:10.15585/mmwr.mm6950a6 — The pivotal update to single-dose 500 mg ceftriaxone monotherapy, driven by antimicrobial stewardship and rising azithromycin resistance.
  3. Unemo M, Shafer WM. Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future. Clinical Microbiology Reviews. 2014;27(3):587–613. doi:10.1128/CMR.00010-14 — A detailed review tracing how the gonococcus defeated each antibiotic class in turn.
  4. Unemo M, Seifert HS, Hook EW, Hawkes S, et al. Gonorrhoea. Nature Reviews Disease Primers. 2019;5:79. doi:10.1038/s41572-019-0128-6 — An authoritative overview of the biology, disease, diagnosis, and treatment of gonorrhea.
  5. Wi T, Lahra MM, Ndowa F, Bala M, et al. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLOS Medicine. 2017;14(7):e1002344. doi:10.1371/journal.pmed.1002344 — The WHO surveillance (GASP) perspective on why global monitoring and new drugs are urgently needed.
  6. Quillin SJ, Seifert HS. Neisseria gonorrhoeae host adaptation and pathogenesis. Nature Reviews Microbiology. 2018;16(4):226–240. doi:10.1038/nrmicro.2017.169 — How pili, Opa proteins, and antigenic variation let the gonococcus evade immunity.
  7. Rice PA, Shafer WM, Ram S, Jerse AE. Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development. Annual Review of Microbiology. 2017;71:665–686. doi:10.1146/annurev-micro-090816-093530 — A synthesis of resistance mechanisms and the challenges of building a vaccine.
  8. Fifer H, Saunders J, Soni S, Sadiq ST, et al. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae. International Journal of STD & AIDS. 2020;31(1):4–15. doi:10.1177/0956462419886775 — National management guidance offering an international counterpoint to the CDC approach.
  9. Petousis-Harris H, Paynter J, Morgan J, Saxton P, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. The Lancet. 2017;390(10102):1603–1610. doi:10.1016/S0140-6736(17)31449-6 — The landmark study suggesting a meningococcal B vaccine offers partial cross-protection against gonorrhea.
  10. Kirkcaldy RD, Weston E, Segurado AC, Hughes G. Epidemiology of gonorrhoea: a global perspective. Sexual Health. 2019;16(5):401–411. doi:10.1071/SH19061 — A global look at how common gonorrhea is and how its burden is distributed.

Back to Table of Contents

Connections

Back to Table of Contents